Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (601)	5/2/2001 3:41:07 PM
From: tuck	Respond to of 1784

A couple of Trickle holdings get new coverage today: >>Initiates Ratings On Arena Pharmaceuticals, Bruker Daltonics, Millennium Pharmaceuticals and Waters Corp. MINNEAPOLIS, May 2, 2001 (BUSINESS WIRE) -- Dain Rauscher Wessels equity analyst Todd Nelson today introduced coverage of the following four biotechnology companies: -- Waters Corp. (NYSE: WAT chart, msgs), $55.68, with a Strong Buy-Average Risk rating and 12-month price target of $73. -- Arena Pharmaceuticals Inc. (Nasdaq: ARNA chart, msgs), $20.64, with a Buy-Aggressive Risk rating and 12-month price target of $29. -- Bruker Daltonics Inc. (Nasdaq: BDAL chart, msgs), $13.65, with a Buy-Aggressive Risk rating and 12-month price target of $20. -- Millennium Pharmaceuticals Inc. (Nasdaq: MLNM chart, msgs), $36.46, with a Buy-Aggressive Risk rating and 12-month price target of $54.<< snip Trickle manager will be climbing in Red Rocks near Vegas starting Saturday and will miss most of next week (back by Friday). Counting on fellow TrickleMavens to cover QGENF, BDAL, EBIO, & PBSC. (5/8 - 5/10) PCOP reports after the close today, and CRL and AGNT report tomorrow. A busy earnings season for Trickle! Cheers, Tuck

To: tuck who wrote (601)	5/2/2001 6:09:53 PM
From: nigel bates	Respond to of 1784

They mentioned advantages in crystallizing GPCR-related and membrane bound proteins? That rings a bell - Message 15708446 However, substantial progress in this field has been hampered so far by the frustrating experience that GPCRs are extremely difficult to purify and crystallize. In fact, the naturally abundant visual pigment rhodopsin is the only GPCR with known 3D structure. m-phasys has overcome a major obstacle by applying its proprietary M-FOLD refolding technology. The large amounts of purified, homogeneous receptors are ideally suited for crystallization experiments...

To: tuck who wrote (601)	5/2/2001 7:15:42 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1784

Tuck: I listened to the MDS Proteomics CBIC presentation. Very poor audio quality, so I missed some very key claims (something about having searched the whole of the yeast proteome in 6 seconds?!? Can't be right). The beginning and end were most informative, so if the audio presentation goes up on the website, skip the middle. This is all in the context of constructing a HT proteomics factory from scratch. They are somewhere in the first 1/3, my guess. So this was mostly about strategy and goals. (In my words, from my notes:) '1. We will move into products (therapeutics). We have been planning for this from day 1, 18 months ago. First stage for MDSP, however, will be via collaborative partnerships. 2. We are not looking simply to generate targets. We are going to do the in-depth tissue work from mapping, to functional characterization, to targeting, validation, structural determination and either antibody or small molecule therapeutics. 3. Currently using multple MS modalities, one gel-free. 30 machines are working, and have been for 6 months, but still need to be integrated with biology and informatics. Have 7 targets from their discoveries, and 120 patents filed. 4. Forward milestones are the characterization of complete, new intracellular signalling pathways in inflammation and oncology; proof of principle (their system) in comparison to yeast 2-hybrid. 5. In 2001, expect one antigen/antibody partnership, a pathway mapping partnership, and a membrane mapping (in one area) partnership. 6. Next 12-18mos, publish the entire proteome of one representative human cell, to be their baseline model of a proteome; two drug candidates in preclinical development; and have formed a chemistry alliance/partnership. (Need hardcore chemistry.)' 7. To emphasize that they will have their own drugs, the speaker commented on how nice it will be to have MDS as a parent/affiliate to do all the preclinical and CRO work, because MDSP will preserve greatest value at the time of future licensing (this is obviously a little inconsistent with the initial plans to partner from the start; and MDS doesn't work for free). So it looks like it will be closest to the OGSI model, though more collaborative at first. I found the comments about needing chemistry very interesting. Axph can't be long alone. What are the other great free standing chemistry labs? There's a few in San Diego I think. Overall, for a large account that wants some safety and somewhat hidden exposure to life sciences, including proteomics, plus a dividend, and that doesn't want to watch the screen or read the news every minute, MDS is worth a hard look. 'Large account' pretty much excludes most of us, but hey... Wilder